Jazz Pharma Announces Commercial Availability In Canada Of Zepzelca - Quick Facts

Jazz Pharmaceuticals plc (JAZZ) announced the commercial availability in Canada of Zepzelca (lurbinectedin), the first new treatment in Canada for adult patients with stage III or metastatic small cell lung cancer who have progressed on or after platinum-containing therapy in more than a decade.

Zepzelca received conditional approval by Health Canada in September 2021. The company noted that the Health Canada conditional approval was based on overall response rate and duration of response. The planned confirmatory study will be started later in the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT